The Quantitative Imaging Biomarkers Alliance (QIBA) was organized by RSNA in 2007 to unite researchers, healthcare professionals, and industry stakeholders in the advancement of quantitative imaging and the use of biomarkers in clinical trials and practice.

Quantitative imaging is the acquisition, extraction and characterization of relevant quantifiable features from medical images for use in research and patient care. Standardizing the use of imaging biomarkers in clinical trials will reduce the variance inherent across different hardware and software platforms. RSNA views this work as a step toward an ultimate goal of enhancing the use of quantitative imaging methods in clinical practice.

QIBA is an important part of RSNA’s commitment to transforming radiology from a qualitative to a more quantitative science and to the improved patient care resulting from accelerated development and dissemination of new pharmacologic, biologic and interventional diagnosis and treatment approaches.

**QIBA Mission**

*Improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices, patients and time.*

The work of QIBA has advanced through the generous efforts of volunteer members from academia, the medical device industry, the pharmaceutical and other business sectors, and government. There are nine biomarker committees open to all interested persons. These Committees have specific tasks and deliverables for their respective modalities and disease-based approach:

- CT Volumetry
- Lung Density
- fMRI
- MRE
- Perfusion, Diffusion and Flow MRI (PDF-MRI)
- FDG-PET/CT
- PET-Amyloid
- SPECT
- Ultrasound Shear Wave Speed (US-SWS)

**The QIBA Approach**

The work of the QIBA Committees follows a defined, coordinated process to develop solutions and promote their adoption.

I. **Identify Sources of Error and Variation in Quantitative Results from Imaging Methods:** Stakeholders work to identify problems leading to error or variability in quantitative results from imaging methods.

II. **Specify Potential Solutions:** Stakeholders identify potential strategies and infrastructure for error mitigation and collaborate on development of hardware, software, and protocol solutions, documenting them in the form of QIBA Profiles.

III. **Test Solutions:** Vendors and researchers implement QIBA solutions to assess their feasibility and efficacy.

IV. **Promulgate Solutions:** Validated solutions are disseminated and implemented through vendor adoption, research integration and clinical education.

**QIBA Resources**

QIBA meeting summaries, key criteria for identifying biomarker opportunities, the *QIBA Newsletter* and other documents are available on the QIBA website RSNA.ORG/QIBA and wiki http://qibawiki.rsna.org/

Volunteers for the QIBA Committees are welcome; please contact us at: qiba@rsna.org
# QIBA Committees

## QIBA Governance Structure

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>QIBA Chair</td>
<td>Edward F. Jackson, PhD</td>
<td>University of Wisconsin, School of Medicine &amp; Public Health</td>
</tr>
<tr>
<td>QIBA Vice Chair</td>
<td>Eric S. Perlman, MD</td>
<td>Perlman Advisory Group, LLC</td>
</tr>
<tr>
<td>Scientific Liaison CT</td>
<td>Andrew J. Buckler, MS</td>
<td>Elucid Bioimaging, Inc.</td>
</tr>
<tr>
<td>Scientific Liaison MR</td>
<td>Thomas L. Chenevert, PhD</td>
<td>University Michigan Health System</td>
</tr>
<tr>
<td>Scientific Liaison NM</td>
<td>Paul E. Kinahan, PhD</td>
<td>University of Washington</td>
</tr>
<tr>
<td>Scientific Liaison US</td>
<td>Paul L. Carson, PhD</td>
<td>University of Michigan Health System</td>
</tr>
</tbody>
</table>

## Process Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Kevin O'Donnell, MASc</td>
<td>Toshiba Medical Research Institute USA, Inc.</td>
</tr>
<tr>
<td>Vice Chair</td>
<td>Daniel Sullivan, MD</td>
<td>Duke University Medical Center</td>
</tr>
</tbody>
</table>

## Coordinating Committees

### Computed Tomography (CT) Coordinating Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Chairs</td>
<td>Greg Goldmacher, MD, PhD, MBA</td>
<td>Merck</td>
</tr>
<tr>
<td></td>
<td>Lawrence Schwartz, MD</td>
<td>New York Presbyterian Hospital/Columbia University</td>
</tr>
<tr>
<td>Vice Chair</td>
<td>David Lynch, MD</td>
<td>National Jewish Health</td>
</tr>
</tbody>
</table>

### Nuclear Medicine (NM) Coordinating Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Chairs</td>
<td>Richard Wahl, MD</td>
<td>Mallinckrodt Institute, Washington University</td>
</tr>
<tr>
<td></td>
<td>Eric Perlman, MD</td>
<td>Perlman Advisory Group, LLC</td>
</tr>
<tr>
<td>Vice Chair</td>
<td>P. David Mozley, MD</td>
<td>Endocyte, Inc.</td>
</tr>
</tbody>
</table>

### Magnetic Resonance Imaging (MR) Coordinating Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-Chairs</td>
<td>Alex Guimaraes, MD, PhD</td>
<td>Oregon Health Sciences University</td>
</tr>
<tr>
<td></td>
<td>Gudrun Zahlmann, PhD</td>
<td>Roche Pharmaceuticals</td>
</tr>
<tr>
<td>Vice Chair</td>
<td>Cathy Elsinger, PhD</td>
<td>NordicNeuroLab, Inc.</td>
</tr>
</tbody>
</table>

### Ultrasound (US) Coordinating Committee

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Tim Hall, PhD</td>
<td>University of Wisconsin, School of Medicine &amp; Public Health</td>
</tr>
<tr>
<td>Vice Chair</td>
<td>Brian Garra, MD</td>
<td>Washington DC VA Medical Center/FDA</td>
</tr>
</tbody>
</table>
Biomarker Committees (by imaging modality)

CT Volumetry
Co-Chairs:
Samuel G. Armato III, PhD (University of Chicago)
Gregory V. Goldmacher, MD, PhD, MBA (Merck)
Jenifer Siegelman, MD, MPH (Harvard Medical School/Brigham and Women's Hospital)

Lung Density
Chair:
Sean Fain, PhD (University of Wisconsin, School of Medicine & Public Health)
Matthew Fuld, PhD (Siemens Medical Solutions USA, Inc.)
David Lynch, MD (National Jewish Health)

Perfusion, Diffusion and Flow - MRI
Co-Chairs:
Michael Boss, PhD (NIST)
John Kirsch, PhD (Siemens Medical Solutions USA, Inc.)
Mark Rosen, MD, PhD (University of Pennsylvania)

fMRI
Co-Chairs:
Edgar DeYoe, PhD (Medical College of Wisconsin)
Jeffrey Petrella, MD (Duke University Medical Center)
James Reuss, PhD (Prism Clinical Imaging, Inc.)

MRE
Co-Chairs:
Patricia Cole, PhD, MD (Takeda Pharmaceuticals)
Richard Ehman, MD (Mayo Clinic)

FDG-PET
Co-Chairs:
Rathan Subramaniam, MD, PhD, MPH (Johns Hopkins University School of Medicine)
John J. Sunderland, PhD (University of Iowa)
Scott Wollenweber, PhD (GE Healthcare)

PET-Amyloid
Co-Chairs:
Satoshi Minoshima, MD, PhD (University of Utah)
Eric Perlman, MD (Perlman Advisory Group, LLC)
Anne Smith, PhD (Siemens Medical Solutions USA, Inc.)

SPECT
Co-Chairs:
Yuni Dewaraja, PhD (University of Michigan)
P. David Mozley, MD (Endocyte, Inc.)
John Seibyl, MD (Yale University/Institute for Neurodegenerative Disorders)

Ultrasound Shear Wave Speed
Co-Chairs:
Brian Garra, MD (Washington DC VA Medical Center/FDA)
Timothy J. Hall, PhD (University of Wisconsin, School of Medicine & Public Health)
Andy Milkowski, MS (Siemens Medical Solutions USA, Inc.)

Updated 4-Sept-2015